Drug Trial Radar · NCT00127647
An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)
Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,375
Actual
Start
Nov 2004
Primary completion
Apr 2005
Study completion Apr 2005
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Aug 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.
Conditions
- Rhinitis, Allergic, Seasonal
Interventions
montelukast sodiumDrug
montelukast sodium; 5 mg, 10 mg QD 2-weeks.
Comparator: pranlukastDrug
Pranlukast 225 mg BID 2-weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Nasal Symptom Score
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.